Anticoagulation of Systemic Sclerosis Patients In Question PDF Print E-mail
Saturday, 18 May 2013 23:43
Australia is in a state of ‘clinical equipoise’ over whether to anticoagulate systemic sclerosis patients with pulmonary hypertension, experts say. And with observational studies showing the treatment is associated with a  fivefold reduction in mortality, the issue demanded a prompt resolution, the team of rheumatologists wrote in this week’s Internal Medicine Journal.

Describing the issue as one of the “most contentious” in the management of patients with connective tissue disease, the doctors said anticoagulation was currently not regarded as standard care in these patients.

A previous study conducted by the authors had revealed that warfarin was used in around 30% of patients, with no Australian centres routinely anticoagulating patients. Practice also varied internationally, they said.

Acknowledging that systemic sclerosis patients had specific bleeding risks that made INR monitoring challenging, the authors said the recent advent of orally administered Xa inhibitors could overcome some of these issues.

“The preliminary evidence favouring a survival benefit with anticoagulation administered in conjunction with PAH-specific therapy makes a compelling case for evaluating its therapeutic efficacy in SSc-PAH,” the study authors wrote.

The authors called for a randomised controlled trial, arguing that a placebo arm was ethically justifiable because of uncertainty around the benefits and relative risks. “The substantially shortened life expectancy of patients with SSc-PAH further adds an element of urgency to the need to resolve this contentious issue,” they added.

Source: Rheumatology Update (2013), "Anticoagulant conundrum for PAH sclerosis"; original article can be viewed here.

 
More articles :

» A Brief History of Scleroderma

While scleroderma may not be very well known to the average person, investigation reveals it has been around for a long time.Classical ReferencesCases of skin disease similar to scleroderma may be found in the writings of Hippocrates as far back as...

» Multidisciplinary Therapy May Improve Systemic Sclerosis

For patients with (SSc), a multidisciplinary program offers better improvement of grip strength, maximal mouth opening (MMO), six-minute walk distance (6MWD), and SSc Health Assessment Questionnaire (HAQ) score than regular outpatient care,...

» Special Surgery Scientists To Share Advances in Lupus and Related Conditions

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of...

» Therapies for Scleroderma-related Pulmonary Arterial Hypertension

Paul M. HassounPosted: 08/20/2009; Expert Rev Resp Med. 2009;3(2):187-196. © 2009 Expert Reviews Ltd.Pulmonary arterial hypertension (PAH), a common complication of systemic sclerosis, carries a very severe prognosis and is one of the leading...

» Types of Stem Cell Treatments for Scleroderma

is a slowly debilitating terminal illness that robs the skin, limbs and vital organs through the process of pain upon exposure to cold and the tightening, thickening and in-elasticity of the skin. Scleroderma deposits connective tissue in places...

» Calcium Deposits Under the Skin

Numerous health effects or conditions are associated with calcinosis or calcium deposits under the skin. According to the , calcinosis is the medical term for calcium deposits that can form under the skin or in the muscles. Calcium deposits in these...